Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
02-25-2014, 10:30 PM (This post was last modified: 02-25-2014, 10:32 PM by OMMP PAY IT FORWARD.)
<a>Science: Clinical phase III study with the cannabis extract Cannador successful in multiple sclerosis</a>
![[Image: multiple-sclerosis0.png]](http://www.insidershealth.com/img/upload/multiple-sclerosis0.png)
A clinical study with the standardized cannabis extract Cannador was recently completed in 279 patients with multiple sclerosis suffering from muscle stiffness under the guidance of Dr John Zajicek, professor at the Peninsula Medical School, Plymouth/UK. The study met its primary objective to show superiority of Cannador over placebo in the treatment of muscle stiffness. The cannabis extract was also superior to placebo with regard to secondary efficacy parameters such as pain, muscle spasms, quality of sleep, and questionnaires on severity of spasticity and overall disability due to multiple sclerosis.
The study, which has been conducted in 22 centres in the UK, was sponsored by the Society for Clinical Research, Germany, and the pharmaceutical company Weleda, Switzerland. It was a randomized, double-blind, placebo-controlled, phase III study, in which 143 patients received the encapsulated cannabis extract and 134 a placebo. Each capsule of Cannador contained 2.5 mg THC (dronabinol) and about 1.25 mg CBD (cannabidiol). Patients received the extract or the placebo for 12 weeks, of which the first two weeks were used to find the individual dose of each patient.
A clinical study with the standardized cannabis extract Cannador was recently completed in 279 patients with multiple sclerosis suffering from muscle stiffness under the guidance of Dr John Zajicek, professor at the Peninsula Medical School, Plymouth/UK. The study met its primary objective to show superiority of Cannador over placebo in the treatment of muscle stiffness. The cannabis extract was also superior to placebo with regard to secondary efficacy parameters such as pain, muscle spasms, quality of sleep, and questionnaires on severity of spasticity and overall disability due to multiple sclerosis.
The study, which has been conducted in 22 centres in the UK, was sponsored by the Society for Clinical Research, Germany, and the pharmaceutical company Weleda, Switzerland. It was a randomized, double-blind, placebo-controlled, phase III study, in which 143 patients received the encapsulated cannabis extract and 134 a placebo. Each capsule of Cannador contained 2.5 mg THC (dronabinol) and about 1.25 mg CBD (cannabidiol). Patients received the extract or the placebo for 12 weeks, of which the first two weeks were used to find the individual dose of each patient.